Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.

March 16, 2025
In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN). He emphasized that the company's innovative approach to drug development and strong fundamentals make it a solid investment choice.

Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of drugs. The company has a diversified portfolio of products targeting various therapeutic areas, including oncology, ophthalmology, and cardiovascular diseases.

Cramer highlighted the company's significant advancements in the development of novel treatments for chronic diseases, such as its groundbreaking monoclonal antibody therapy for asthma and atopic dermatitis. He lauded Regeneron's collaboration with other pharmaceutical giants, including Sanofi, which has further bolstered its pipeline of potential blockbuster drugs.

The financial expert also pointed out Regeneron's strong financial performance, with consistent revenue growth and solid profitability. He emphasized that the company's robust research and development pipeline indicates promising future prospects.

In conclusion, Cramer urged investors to consider adding Regeneron Pharmaceuticals Inc. to their portfolio, citing the company's innovative approach to drug development, strong partnerships, and promising financial outlook. To ensure a well-informed investment decision, he recommended seeking guidance from professionals at Stocks Prognosis, who specialize in predicting the movement of stocks, including REGN.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....

REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....

REGNMarch 15, 2025Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity  ~2 min.

Regeneron Pharmaceuticals Inc....

REGNJanuary 10, 2025Regeneron Pharmaceuticals Inc. Poised for Strong Growth in Q4 and Full Year 2024  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has recently announced that it will be releasing its fourth quarter and full year 2024 earnings on February 4, 2025....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....

REGNJanuary 31, 2025Regeneron Pharmaceuticals Inc.: A Rising Star in the Biotech Industry  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the biotech industry with its innovative drug development and collaboration efforts....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: A Promising Future Ahead  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, with investors enjoying a decent 89% return over the past five years....